R&D Expenditures and Market Value of Biotechnology Firms

• Autorzy: Piotr Chojnacki , Tomasz Kijek

Warianty tytułu

Wydatki na prace badawczo-rozwojowe a wartość rynkowa firm biotechnologicznych

• Języki publikacji: EN

Abstrakty

EN

The aim of this paper is to conduct an analysis of R&D investments and their impact on a biotechnology firm's value. The sample consists of the top 52 R&D investors from the European biotechnology sector. The data were obtained from "EU Industrial R&D Investment Scoreboard". The multiple linear regression was applied to find the answer to the research question. The main findings of the study reveal that there is a positive relationship between the firm's investment in R&D and the market value. (original abstract)

Celem opracowania było określenie wpływu inwestycji w działalność badawczo-rozwojową (B+R) na wartość rynkową firm biotechnologicznych. Próba badawcza składała się z 52 firm biotechnologicznych będących największymi inwestorami w działalność B+R. Dane wykorzystane w opracowaniu pochodzą z Europejskiego Rankingu Inwestorów w B+R. W badaniu wykorzystano model regresji wielorakiej. Uzyskane wyniki wskazują, że inwestycje w B+R mają pozytywny wpływ na wartość rynkową badanych przedsiębiorstw. (abstrakt oryginalny)

Słowa kluczowe

EN

Biotechnology; R&D in the enterprise; Market value of enterprise

PL

Biotechnologia; Sfera B+R w przedsiębiorstwie; Wartość rynkowa przedsiębiorstwa

• Czasopismo: Roczniki Naukowe Stowarzyszenia Ekonomistów Rolnictwa i Agrobiznesu
• Rocznik: 2014
• Tom: 16
• Numer: z. 6
• Strony: 77--81

Twórcy

autor

Piotr Chojnacki

• University of Life Sciences in Lublin, Poland

autor

Tomasz Kijek

• University of Life Sciences in Lublin, Poland

Bibliografia

• Aiken L.S., West S.G. 1991: Multiple regression: Testing and interpreting interactions, Sage, Newbury Park, 32-34.
• Al-Laham A., Tzabbar D., Amburgey T.L. 2011: The Dynamics of Knowledge Stocks and Knowledge Flows: Innovation Consequences of Recruitment and Collaboration in Biotech, Industrial and Corporate Change, vol. 20, no. 2, 555-583.
• Barth M.E., Kallapur S. 1996: The Effects of Cross-Sectional Scale Differences on Regressions Results in Empirical Accounting Research, Contemporary Accounting Research, vol. 13, 527-567.
• Blank S. 2008: Small and Medium Enterprises in Agricultural Biotechnology, www.oecd.org/dataoecd/11/59/40925488.pdf, access: 15.09.2014.
• Callen J., Gavious I., Segal D. 2010: The complementary relationship between financial and non-financial information in the biotechnology industry and the degree of investor sophistication, Journal of Contemporary Accounting & Economics, vol. 6, 61-76.
• Enzing C. 2011: Sectoral Innovation Watch. Biotechnology Sector, http://ec.europa.eu/enterprise/policies/innovation/files/proinno/sector-report-biotechnology_en.pdf, access: 15.09.2014.
• Fama E.F. 1991: Efficient capital markets, Journal of Finance, vol. 46, no. 5, 1575 1617.
• Griliches Z. 1981: Market Value, R&D, and Patents, Economic Letters, vol. 7, no. 2, 183-187.
• Hall B.H. 2000: Innovation and Market Value, [In:] R. Barrell, G. Mason, M. O'Mahoney, (eds.), Productivity, Innovation and Economic Performance, Cambridge University Press, Cambridge, 177-198.
• Hall B., Thoma G., Torrisi S. 2007: The market value of patents and R&D: Evidence from European firms, www.nber.org/papers/w13426, access: 15.09.2014.
• Hand J.R.M. 2004: The market valuation of biotechnology firms and biotechnology R&D, [in:] J. Mccahery, L. Renneboog (eds.), Venture Capital Contracting and the Valuation of High-Technology Firms Oxford University Press, Oxford, 251-280.
• Hine D. Kapeleris J. 2006: Innovation and Entrepreneurship in Biotechnology, an International Perspective: Concepts, Theories and Cases, Edward Elgar Publishing, Cheltenham, 20.
• Kijek T. 2014: Market valuation of innovation capital, International Journal of Innovation and Learning, vol. 15, no. 4, 411-421.
• OECD Biotechnology Statistics. 2009:OECD, Paris, 9.
• Piergiovanni R., Santarelli E. 2013: The more you spend, the more you get? The effects of R&D and capital expenditures on the patenting activities of biotechnology firms, Scientometrics, vol. 94, 497-521.
• Pisano G. 2006: Science Business: The Promise, The Reality, and The Future of Biotech, Harvard Business School Press: Boston, 111-112.
• Shevlin T. 1996: The value-relevance of nonfinancial information: A discussion, Journal of Accounting and Economics, vol. 22, no. 1-3, 31-42.
• Xu B., Magnan M., Andre P. 2007: The stock market valuation of R&D information in biotech firms, Contemporary Accounting Research, vol. 24, 1291-1318.